GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geron Corp (NAS:GERN) » Definitions » Shiller PE Ratio
中文

Geron (GERN) Shiller PE Ratio : (As of Apr. 25, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Geron Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Geron Shiller PE Ratio Historical Data

The historical data trend for Geron's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geron Shiller PE Ratio Chart

Geron Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Geron Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Geron's Shiller PE Ratio

For the Biotechnology subindustry, Geron's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Geron's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geron's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Geron's Shiller PE Ratio falls into.



Geron Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Geron's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Geron's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.09/129.4194*129.4194
=-0.090

Current CPI (Dec. 2023) = 129.4194.

Geron Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.060 99.695 -0.078
201406 -0.060 100.560 -0.077
201409 -0.060 100.428 -0.077
201412 -0.060 99.070 -0.078
201503 -0.060 99.621 -0.078
201506 -0.060 100.684 -0.077
201509 0.170 100.392 0.219
201512 -0.050 99.792 -0.065
201603 -0.060 100.470 -0.077
201606 -0.050 101.688 -0.064
201609 -0.020 101.861 -0.025
201612 -0.050 101.863 -0.064
201703 -0.050 102.862 -0.063
201706 -0.040 103.349 -0.050
201709 -0.040 104.136 -0.050
201712 -0.050 104.011 -0.062
201803 -0.040 105.290 -0.049
201806 -0.040 106.317 -0.049
201809 -0.030 106.507 -0.036
201812 -0.040 105.998 -0.049
201903 -0.050 107.251 -0.060
201906 -0.080 108.070 -0.096
201909 -0.080 108.329 -0.096
201912 -0.150 108.420 -0.179
202003 -0.080 108.902 -0.095
202006 -0.060 108.767 -0.071
202009 -0.060 109.815 -0.071
202012 -0.070 109.897 -0.082
202103 -0.090 111.754 -0.104
202106 -0.090 114.631 -0.102
202109 -0.080 115.734 -0.089
202112 -0.100 117.630 -0.110
202203 -0.090 121.301 -0.096
202206 -0.070 125.017 -0.072
202209 -0.100 125.227 -0.103
202212 -0.100 125.222 -0.103
202303 -0.070 127.348 -0.071
202306 -0.090 128.729 -0.090
202309 -0.080 129.860 -0.080
202312 -0.090 129.419 -0.090

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Geron  (NAS:GERN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Geron Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Geron's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Geron (GERN) Business Description

Traded in Other Exchanges
Address
919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. the company operates as a single segment, the development of therapeutic products for oncology.
Executives
Michelle Robertson officer: EVP, Chief Financial Officer C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Elizabeth G. O'farrell director 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Scott Alan Samuels officer: EVP, Chief Legal Officer 919 E. HILLSDALE BLVD., SUITE 250, FOSTER CITY CA 94404
V Bryan Lawlis director
Susan Molineaux director C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
John A Scarlett director, officer: Chief Executive Officer C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Andrew J Grethlein officer: EVP, Technical Operations 651 GATEWAY BLVD STE 950, SOUTH SAN FRANCISCO CA 94080
Olivia Kyusuk Bloom officer: Controller, Chief Acctg Off C/O GERON CORP, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
John F Mcdonald director C/O GERON CORPORATION, 919 EAST HILLSDALE BLVD., SUITE 250, FOSTER CITY CA 94404
Faye Feller officer: EVP, Chief Medical Officer 919 EAST HILLSDALE BOULEVARD, SUITE 250, FOSTER CITY CA 94404
Anil Kapur officer: EVP, Corp Strategy & CCO 275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Melissa Kelly officer: VP, Oncology 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Dawn Carter Bir director C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DRIVE, SUITE 150, IRVING TX 75063
Aleksandra Rizo officer: EVP, Chief Medical Officer C/O GERON CORPORATION, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025